How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
DNA Ginkgo Bioworks Holdings, Inc.
On March 31, 2026, the Federal Court will hold a hearing to decide whether it will approve a proposed settlement agreement in the Sweet Class Action. Learn more about the proposed settlement and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results